| CAS NO: | 1420071-30-2 |
| 包装 | 价格(元) |
| Free Sample (0.1-0.5mg) | 电议 |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 200mg | 电议 |
| 500mg | 电议 |
| Cas No. | 1420071-30-2 |
| 别名 | DR5 Activator |
| Canonical SMILES | O=C(/C(SC1=N)=C/C2=CC=C(O2)C3=CC(C(N4)=O)=C(C=C3)C4=O)N1C5=CC=C(C=C5)Br |
| 分子式 | C22H12BrN3O4S |
| 分子量 | 494.32 |
| 溶解度 | DMSO: 12.5 mg/mL (25.29 mM) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Bioymifi(DR5 Activator) is the first novel and potent small-molecule activatior of the TRAIL receptor DR5 in human cancer cells.IC50 value:Target: In comparison with A2C2, bioymifi was able to promote cell death without the need for the Smac mimetic in T98G cells. Notably, at a 10-μM concentration, bioymifi induced processing of caspase-3 into smaller fragments. Z-VAD inhibited these caspase-mediated cleavages. caspase-3 was rapidly activated as early as 2 h after bioymifi treatment of T98G cells. The caspase-3 activity was markedly increased after 8 h of treatment. Bioymifi induces caspase-8-dependent apoptosis. [1]. Wang G, et al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat Chem Biol. 2013 Feb;9(2):84-9. |
m.cnreagent.com